A phase 2 pilot study of umbilical cord blood infusion as an adjuvant consolidation therapy in elderly patients with acute myeloid leukemia [0.03%]
胎盘血输注用于老年急性髓系白血病患者巩固治疗的II期临床研究
Jinzeng Wang,Xiaoyang Li,Ping Liu et al.
Jinzeng Wang et al.
Acute myeloid leukemia (AML) is an aging-related malignancy, with patients aged ≥60 years old facing significantly poorer prognosis. Umbilical cord blood (UCB) has emerged as a promising source with effective anti-aging roles. Here, we con...
Macrophages promote pre-metastatic niche formation of breast cancer through aryl hydrocarbon receptor activity [0.03%]
芳香烃受体活性通过巨噬细胞促进乳腺癌前转移灶形成
Xu Jiang,Jiaqi Wang,Liangyu Lin et al.
Xu Jiang et al.
Macrophages that acquire an immunosuppressive phenotype play a crucial role in establishing the pre-metastatic niche (PMN), which is essential for facilitating breast cancer metastasis to distant organs. Our study showed that increased acti...
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomized, phase 3 study [0.03%]
高体积转移性激素敏感性前列腺癌患者中瑞唑特帕利联合雄激素剥夺治疗对比比卡鲁肽加雄激素剥夺治疗的患者报告结局：一项随机Ⅲ期研究（CHART）
Hongkai Wang,Shusuan Jiang,Hong Luo et al.
Hongkai Wang et al.
The randomized phase 3 CHART trial (NCT03520478) revealed that rezvilutamide (REZ) plus androgen deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC) significantly enhanced radiographic progression...
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer [0.03%]
SHR-1701联合一线希罗达和奥沙利铂(×ELOX)方案联合贝伐珠单抗治疗不可手术切除的转移性结直肠癌研究
Miao-Zhen Qiu,Yuxian Bai,Jufeng Wang et al.
Miao-Zhen Qiu et al.
This phase 2/3 trial (NCT04856787) assessed the efficacy and safety of SHR-1701, a bifunctional protein targeting PD-L1 and TGF-β, in combination with BP102 (a bevacizumab biosimilar) and XELOX (capecitabine plus oxaliplatin) as a first-li...
Advances in calcium-sensing receptor modulation: biased signaling and therapeutic potential [0.03%]
钙感受器调节研究进展：偏向信号转导和治疗潜力
Luisa Uhlmann,Ulf Wagner
Luisa Uhlmann
Noninvasive early identification of durable clinical benefit from immune checkpoint inhibition: a prospective multicenter study (NCT04566432) [0.03%]
一项前瞻性多中心研究：非侵入性早期识别免疫检查点抑制的持久临床疗效（NCT04566432）
Xinghao Ai,Bo Jia,Zhiyi He et al.
Xinghao Ai et al.
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC). In spite of durable responses in some patients, many patients develop early disease progression during the ICI tr...
Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates [0.03%]
纠正：新一代猴痘疫苗：与 Modified Vaccinia Virus Ankara 疫苗相比，mRNA-1769 在非人灵长类动物中的疗效
Leonie Mayer,Leonie M Weskamm,Marylyn M Addo
Leonie Mayer
Petra Mlcochova,Na Zhao,Omar Shabana et al.
Petra Mlcochova et al.
Bridge over troubled cells: bone marrow stromal cells transfer mitochondria to boost T cells [0.03%]
跨越困境的桥梁：骨髓基质细胞转移线粒体以增强T细胞功能
Lars Fabian Prinz,Roland Tillmann Ullrich,Markus Martin Chmielewski
Lars Fabian Prinz
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial [0.03%]
SHR-1701联合呋喹替尼治疗既往经治的胆管癌和胰腺导管腺癌患者的临床及生物标志物分析：Ⅱ期试验
Lixia Yi,Haoqi Pan,Zhouyu Ning et al.
Lixia Yi et al.
Advanced biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC) have poor prognoses and limited treatment options. Here, we conducted this first-in-class phase II study to evaluate the efficacy and safety of SHR-1701, a bifu...